ABSTRACT
OBJECTIVE To investigate the effects of individualized dosing regimen on blood trough concentration of vancomycin and renal function in critically ill patients. METHODS According to relevant guidelines and the results of Vancomycin Calculator， clinical pharmacists formulated an individualized dosing regimen of vancomycin including loading dose and maintenance dose for critically ill patients based on the two independent variables of body weight and creatinine clearance rate. Using the method of retrospective study， patients who were admitted to the department of intensive care unit （ICU） of the Second Affiliated Hospital of Guangzhou Medical University and used the regimen from July 2018 to December 2021 were selected as the trial group， and patients who were treated with vancomycin and received blood drug concentration monitoring in ICU from January 2015 to June 2018 were recruited in the control group. The difference in trough concentration distribution and the incidence of acute kidney injury （AKI） after medication were compared between the two groups， the change of serum creatinine before and after medication in the trial group was analyzed. RESULTS Totally 197 patients were included in the trial group and 144 patients were in the control group. There was no significant difference between the two groups in the clinical information （gender， age， body weight， acute physiology and chronic health evaluation Ⅱ score， the proportion of patients with renal insufficiency， etc.） （P＞0.05）. The proportions of major infection sites （including lung， urinary， abdominal， blood and central nervous system） and treatment type （target or empirical treatment） also had no significant difference between the two groups （P＞0.05）. There was no significant difference in the attainment rate of ideal trough concentration （15-20 μg/mL） and the proportion of patients with trough concentration ＞20 μg/mL between the two groups （P＞0.05）， while the attainment rate of target trough concentration （10-20 μg/mL） and the proportion of patients with trough concentration ＜10 μg/mL were significantly different between the two groups （P＜0.05）. The attainment rate of target trough concentration in patients with chronic renal insufficiency in trial group was significantly higher than that in control group （P＜0.05）. There was no significant difference in the incidence of AKI and vancomycin-associated AKI between the two groups （P＞0.05）. In the trial group with medication duration ≥7 days ， the level of serum creatinine on the 7th day of treatment was increased significantly， compared with that on the 3rd day of treatment （P＜0.05）. CONCLUSIONS This individualized dosing regimen can improve the attainment rate of target trough concentration of vancomycin in critically ill patients， especially those with chronic renal insufficiency， during the first standardized monitoring， and not increase the risk of renal injury compared with previous empirical medication.
ABSTRACT
With the progress of dose individualization theory and research, decision-making systems have increasingly emerged in recent years. In this paper, common individualized dosing computer program, web platform and application on mobile devices are identified and summarized by searching literatures and internet, and compared with each other in terms of general characteristics and professional characteristics. Twenty-five systems are included in total. These systems, which estimate parameters mostly by Bayesian algorithm, cover anti-bacterial drugs and antiviral drugs, immunosuppressants, anti-tumor drugs, nervous system drugs, cardiovascular system drugs, respiratory system drugs and so on. MwPharm++, a commercial computer program, has the best comprehensive performance among all these. Besides, highlighted advantages are showed in commercial computer program Precise PK, APK, free computer program JPKD, BestDose and web platform SmartDose. Along with the development of internet and the high performance computing tools, mobile apps are booming. It is expected that the decision-making systems to be developed and promoted continuously in the future and could provide more options and references for clinical individualized dosing.
ABSTRACT
This article describes the definition of the term TDM (i. e. therapeutic drug monitoring), presents the past history, present status and future prospects of individualized dosing regimen, and emphasizes the role of population pharmacokinetics and one point feedback Bayesian method played in the design of dosing regimen.